Amgen and UCB Provide Regulatory Update on Status of EVENITY ™ (romosozumab) in the EU
THOUSAND OAKS, Calif. and BRUSSELS, June 27, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Application for EVENITYTM (romosozumab) for the treatment of severe osteoporosis. The companies intend to submit a written notice for a re-examination by the CHMP. "After a fracture, postmenopausal women with osteoporosis are five times more likely to fracture in the subsequent year,1 a...
Source: Amgen News Release - June 28, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket
Two Biotherapeutic Companies Receive Lab Space and Other Benefits to Further Advance Innovative Science at Bay Area Life Sciences Incubator SAN FRANCISCO, June 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) today announced that Regencor and Nitrome Biosciences have each been awarded an Amgen Golden Ticket to MBC BioLabs. The companies receive priority admission or renewal for one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen's scientific and business leaders to help advance their scientif...
Source: Amgen News Release - June 25, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership
Collaboration Will Apply IPD's de novo Protein Design Expertise to Biotech Drug Discovery THOUSAND OAKS, Calif. and SEATTLE, June 19, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and the University of Washington's Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health, today announced a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building approaches that can be broadly applied to the search for new medicines. Under the terms of the agreement, Amg...
Source: Amgen News Release - June 19, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces BLINCYTO ® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months in Patients With Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia More Than Half of Patients who Achieved an MRD-Negative Complete Response Still Alive at Five Years Only CD19-Targeted Immuno-oncology Therapy With Five-Year Survival Data THOUSAND OAKS, Calif., June 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO® (blinatumomab) in patients with minimal residual disease (MRD)-positive acute lympho...
Source: Amgen News Release - June 16, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Amgen And Allergan's KANJINTI ™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. "...
Source: Amgen News Release - June 14, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution
THOUSAND OAKS, Calif., June 12, 2019 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. Shareholders in the Un...
Source: Amgen News Release - June 12, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Intermountain Healthcare and deCODE genetics Launch Groundbreaking DNA Study of 500,000 People to Find New Links Between Genetics and Disease
Study Represents Largest  DNA Mapping Effort Undertaken in U.S. from a Single PopulationREYKJAVIK, ICELAND, and SALT LAKE  CITY – Intermountain Healthcare and  deCODE genetics have announced a major global collaboration and study focused  on discovering new connections between genetics and human disease that will  involve the collection of half a million DNA samples. The initiative, called the  HerediGene: Population Study, represents the largest and most comprehensive DNA  mapping effort to date in the United States from a single population. For the  study, which is voluntary ...
Source: Amgen News Release - June 12, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
THOUSAND OAKS, Calif., June 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 11:20 a.m. PT on Wednesday, June 12, 2019, in Rancho Palos Verdes, Calif. David M. Reese, M.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. About Amgen Amgen is committed to unlocking the pot...
Source: Amgen News Release - June 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019
AMG 510 is the First KRASG12C Inhibitor to Reach Clinical Stage After Three Decades of RAS Research First-In-Human Results Show Preliminary Safety, Tolerability Data and Anti-Tumor Activity in KRAS Mutant Solid Tumors FDA Grants AMG 510 Orphan Drug Designation for KRASG12C-Positive Non-Small Cell Lung and Colorectal Cancers THOUSAND OAKS, Calif., June 3, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the first clinical results from a Phase 1 study evaluating investigational AMG 510, the first KRASG12C inhibitor to reach the clinical stage. In the trial, there were no dose-limiting toxicities at tested d...
Source: Amgen News Release - June 3, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Highlights The Versatility Of The BiTE ® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019
Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO® Investigational AMG 212 (Pasotuxizumab) Phase 1 Study Explores Use of BiTE Platform in a Solid Tumor THOUSAND OAKS, Calif., June 2, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from Phase 1 studies evaluating investigational bispecific T cell engager (BiTE®) molecules were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Data presented included updated investigational AMG 42...
Source: Amgen News Release - June 2, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
THOUSAND OAKS, Calif., May 29, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast investor meeting at ASCO 2019 on Monday, June 3 at 6:30 p.m. CT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss Amgen's oncology program and data presented at ASCO 2019 including clinical data being presented for the Company's KRAS G12C inhibitor AMG 510 and BiTE® molecules AMG 420 and AMG 212.   Live audio of the investor meeting will be br...
Source: Amgen News Release - May 29, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution
THOUSAND OAKS, Calif., May 28, 2019 /PRNewswire/ --  The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. Shareholders in t...
Source: Amgen News Release - May 29, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Joins With Community Oncology Networks For New Research Collaboration
Amgen Community Oncology Research Collaborators (ACORC) Will Work to Expand Clinical Trial Access to Cancer Patients Treated Outside of Academic Centers First Members Include US Oncology Research and TRIO-US With UCLA THOUSAND OAKS, Calif., May 28, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiative to enhance access by community centers to innovative oncology clinical research. Fewer than one in 20 adult cancer patients in the U.S. have participated in a clinical trial.1 The...
Source: Amgen News Release - May 28, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen announces a recommended public cash offer to the shareholders of Nuevolution
THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. Shareholders...
Source: Amgen News Release - May 22, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Voting Results Of Annual Meeting Of Stockholders
THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at the meeting. The director nominees Wanda M. Austin, Robert A. Bradway, Brian J. Druker, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Charles M. Holley, Jr., Tyler Jacks, Ellen J. Kullman, Ronald D. Sugar, and R. Sanders Williams were each re-elected to Amgen's Board of Directors. Each director received approximately 96 percent ...
Source: Amgen News Release - May 21, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference
THOUSAND OAKS, Calif., May 16, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at both conferences. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. About Amgen Amgen is committed to unlocking t...
Source: Amgen News Release - May 16, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Showcases Oncology Pipeline At ASCO 2019
Data From Largest Oncology Pipeline in Company's History First-in-Human Data Evaluating Investigational AMG 510, the First KRASG12C Inhibitor to Reach Clinical Stage, in Solid Tumors Potential Versatility of BiTE® Immuno-oncology Platform Reinforced With Phase 1 Asset Updates THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignan...
Source: Amgen News Release - May 15, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference
THOUSAND OAKS, Calif., May 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering f...
Source: Amgen News Release - May 10, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Sets Official Guinness World Record ™ for Most Osteoporosis Screenings for an Osteoporosis Campaign in 24 Hours
Healthcare Campaign  Executed Across 10 Countries to Raise Awareness of the Importance of Predicting  and Preventing Osteoporosis and Bone Fracture, Particularly in Post-Menopausal  WomenThousand Oaks, Calif. (May 6, 2019) – Amgen, together with local healthcare partners in 10 countries around the  world, set on May 5, 2019, a Guinness World Record title for the most  osteoporosis screenings for an osteoporosis campaign in 24 hours. To break the existing world  record, Amgen set out to screen at least a total of 3,000  people in 10 countries around the world -- to  help them un...
Source: Amgen News Release - May 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig ® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting
After Long-Term Aimovig Treatment, Two-Thirds of Chronic Migraine Patients Converted to Episodic Migraine, Experiencing 11 Fewer Migraine Days per Month on Average Separate Study Showed the Majority of Episodic Migraine Patients on Aimovig Reported at Least a 50 Percent Reduction in Monthly Migraine Days at One Year, With One in Five Being Completely Migraine-Free Aimovig is the Most Prescribed Anti-CGRP Therapy - Approximately 200,000 Patients in the U.S. Have Been Prescribed Aimovig Since Launch[1] THOUSAND OAKS, Calif., May 2, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present new lon...
Source: Amgen News Release - May 2, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Syapse Enter Precision Medicine Collaboration In Oncology
Supports Providers With Advanced Insight Tools and Research Opportunities Generates Insights From Real-World Evidence for Potential Use in Regulatory Filings THOUSAND OAKS, Calif. and SAN FRANCISCO, May 2, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, today announced a precision medicine collaboration in oncology. Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology. This eff...
Source: Amgen News Release - May 2, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Ignites A Social Fitness Movement To Support The Fight Against Heart Disease And Cancer
Amgen Breakaway Challenge Turns Walking, Running or Cycling Miles Into Support for Eight Independent Nonprofit Advocacy Organizations THOUSAND OAKS, Calif., May 1, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support the fight against heart disease and cancer. Amgen's Breakaway Challenge joins together Breakaway from Cancer® and Breakaway from Heart Disease™ and serves as a complementary component to its title sponsorship of the Amgen Tour of California, a world-class...
Source: Amgen News Release - May 1, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports First Quarter 2019 Financial Results
THOUSAND OAKS, Calif., April 30, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2019. Key results include: Total revenues were unchanged at $5.6 billion in comparison to the first quarter of 2018. Product sales declined 1 percent globally. New and recently launched products including Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib) showed double-digit growth. GAAP earnings per share (EPS) decreased 2 percent to $3.18 driven by higher total operating expenses, offset partially by lower weighted-average shares outstanding. ...
Source: Amgen News Release - April 30, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Webcast of 2019 First Quarter Financial Results
THOUSAND OAKS, Calif., April 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 30, 2019, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors an...
Source: Amgen News Release - April 25, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida
Long-Established Science Education Program to Give Local Secondary School Students Hands-On Biotechnology Lab Experience TAMPA, Fla., April 17, 2019 /PRNewswire/ -- The Amgen Foundation, together with the University of South Florida (USF), today announced the launch of the Amgen Biotech Experience (ABE) program in Tampa, Florida, as part of its long-standing science education program. Globally, ABE is expected to reach nearly 900,000 secondary school students by 2020 in 20 regions around the world. For nearly 30 years, ABE has empowered high school science teachers to implement real-world biotechnology labs in t...
Source: Amgen News Release - April 17, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

EVENITY ™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
New Therapy to Cost One-Third Less Than Other Bone-Building Agents Over Full Course of Therapy THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture. "Osteoporosis is a silent disease that can lead to devastating consequences. Unfortunately, only 20 percent of women who have experienced a fracture receive any...
Source: Amgen News Release - April 15, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves EVENITY ™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1) EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2) EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2) THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk fo...
Source: Amgen News Release - April 9, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe
Study Shows 55 Percent of Women Over 70 Years Old are at Risk of Fragility Fractures With 75 Percent of Them not Treated for Osteoporosis THOUSAND OAKS, Calif., April 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data presented from a cross-sectional study revealing a gap in the diagnosis and treatment of osteoporosis in Europe. The real-world study of osteoporosis management in primary care revealed that 75 percent of female patients aged 70 years and older who were at increased risk of fragility fractures were not treated for osteoporosis. The treatment gap was much lower in those with a recor...
Source: Amgen News Release - April 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes THOUSAND OAKS, Calif., and SOUTH SAN FRANCISCO, Calif., and SURESNES, France, March 20, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial...
Source: Amgen News Release - March 20, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha ® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
VESALIUS-CV is the Latest Study in Amgen's PROFICIO Clinical Program Investigating the Impact of Repatha on CVD in Multiple Patient Populations Phase 3 Study Will Enroll High-Risk Patients who Have Significant Atherosclerotic Disease or Diabetes and are at High Risk for a First Cardiovascular Event THOUSAND OAKS, Calif., March 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to conduct VESALIUS-CV, a multinational clinical outcomes study for Repatha® (evolocumab) which will involve at least 13,000 patients worldwide at high risk of experiencing a first cardiovascular (CV) event, despite optimiz...
Source: Amgen News Release - March 15, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk
If You've had a Heart Attack or Stroke, Your Risk of Having Another Cardiovascular Event is Nearly One in Three(1) Cholesterol 911 Urges These High-Risk Patients to See the Emergency in High Cholesterol and Talk to Their Doctor About Ways to Reduce the Risk of Another Heart Attack and Stroke THOUSAND OAKS, Calif., March 12, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today launched Cholesterol 911, a national initiative urging high-risk cardiovascular disease patients to reduce their risk of another heart attack or stroke by addressing their continued high LDL-C, or "bad" cholesterol. Comedian and televi...
Source: Amgen News Release - March 12, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces 2019 Second Quarter Dividend
THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019. The dividend will be paid on June 7, 2019, to all stockholders of record as of the close of business on May 17, 2019. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understan...
Source: Amgen News Release - March 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference
THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019, in Boston. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. About Amgen Amgen is committed to unlocking the potential of biology for patient...
Source: Amgen News Release - March 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha ® (evolocumab) Across Multiple Patient Populations
Results From TAUSSIG Study Reinforce Repatha's Safety and Efficacy in Patients With Genetic Risk of High Cholesterol Several Real-World Evidence Studies Highlight Continued Unmet Need and Suboptimal Treatment of High-Risk Cardiovascular Disease Patients THOUSAND OAKS, Calif., March 6, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from the largest and longest open label study of homozygous familial hypercholesterolemia (HoFH) patients (TAUSSIG),1  as well as a sub-analysis from the Repatha...
Source: Amgen News Release - March 6, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019
First Preclinical Data to be Presented on AMG 510, a First-in-Class KRASG12C Inhibitor for Solid Tumors New Preclinical Data Evaluating AMG 757 to Highlight Half-Life Extended BiTE® Immunotherapy AMG 176 Preclinical Data Showcase Potential in Combination With Standard of Care Treatments for Acute Myeloid Leukemia THOUSAND OAKS, Calif., Feb. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its early-stage oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29 – April 3, 2019. "At Amgen, we ar...
Source: Amgen News Release - February 28, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Jury Upholds Amgen's Patents On Repatha ® (evolocumab)
THOUSAND OAKS, Calif., Feb. 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These patents describe and claim antibodies, like Amgen's innovative Repatha® (evolocumab) product, that bind to a specific region on PCSK9 and reduce LDL-C levels in the body. This verdict follows a previous trial in March 2016 where Sanofi and Regeneron admitted infringement of Amgen's patents and where a prior jury also upheld the validity of Amgen's patents. The prior jury decision was partiall...
Source: Amgen News Release - February 25, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of ...
Source: Amgen News Release - February 21, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports Fourth Quarter And Full Year 2018 Financial Results
THOUSAND OAKS, Calif., Jan. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key results include: For the fourth quarter, total revenues increased 7 percent to $6.2 billion. Product sales grew 8 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth. For the full year, total revenues increased 4 percent to $23.7 billion, with 3 percent product s...
Source: Amgen News Release - January 29, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results
THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2018 financial results on Tuesday, Jan. 29, 2019, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news m...
Source: Amgen News Release - January 24, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives NMPA Approval For Repatha ® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events
Innovative LDL-C Lowering Treatment has now Been Approved for High-Risk Patients in China With Cardiovascular Disease THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization. Low-density lipoprotein cholesterol (LDL-C) is one of the key modifiable risk factors for the deve...
Source: Amgen News Release - January 24, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
Study Evaluated Pharmacokinetics, Efficacy and Safety of ABP 798 Compared to Rituximab in Patients With Moderate-to-Severe Rheumatoid Arthritis THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798, a biosimilar candidate to RITUXAN® (rituximab), compared to rituximab in patients with moderate-to-severe rheumatoid arthritis. The results demonstrate that the study met its primary endpoint of pharmacokine...
Source: Amgen News Release - January 24, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

European Commission Approves BLINCYTO ® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
BLINCYTO is the First and Only Therapy for Minimal Residual Disease Approved in the European Union Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Jan. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remissi...
Source: Amgen News Release - January 22, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY ™ (romosozumab)
Potential New Treatment Option for the Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture THOUSAND OAKS, Calif. and BRUSSELS, Jan. 16, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase 3 studies. Eighteen of 19 members vote...
Source: Amgen News Release - January 16, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

EVENITY ™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
EVENITY Approved to Reduce the Risk of Fractures and Increase Bone Mineral Density in Men and Postmenopausal Women With Osteoporosis at High Risk of Fracture EVENITY in Japan is Being Co-Developed Through a Strategic Alliance With Amgen Astellas BioPharma THOUSAND OAKS, Calif. and BRUSSELS, Belgium, Jan. 8, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture.1 Amgen and UCB are c...
Source: Amgen News Release - January 8, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Makes All Repatha ® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
The Repatha Pre-Filled Syringe and Repatha Pushtronex® System are Now Available at a Reduced List Price of $5,850 Majority of Repatha Medicare Patients Now Have Access at a Significantly Lower Out-of-Pocket Cost THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, all Repatha® (evolocumab) device options, including the Pre-Filled Syringe and Pushtronex® (on-body infusor with pre...
Source: Amgen News Release - January 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The 37th Annual J.P. Morgan Healthcare Conference
THOUSAND OAKS, Calif., Jan. 3, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 37th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 8, 2019, in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 9...
Source: Amgen News Release - January 3, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Submits Supplemental Biologics License Application For Nplate ® (romiplostim)
Application Seeks to Include Adult Patients who Have had Immune Thrombocytopenia for 12 Months or Less THOUSAND OAKS, Calif., Dec. 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Nplate® (romiplostim) to include the treatment of adult patients with immune thrombocytopenia (ITP) who have had ITP for 12 months or less and an insufficient response to corticosteroids, immunoglobulins or splenectomy. "Patients living with ITP need more flexibility in their treatment options, and we...
Source: Amgen News Release - December 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology
Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen's Oncology Assets, Including BiTE® Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products THOUSAND OAKS, Calif. and ZURICH-SCHLIEREN, Switzerland, Dec. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics, today announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x...
Source: Amgen News Release - December 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Engages Cambridge Biotech Community To Select 2018 LabCentral Golden Ticket Winners
Amgen Golden Tickets Provide Startup Companies With Free Lab Space to Further Advance Innovative Science and Technology CAMBRIDGE, Mass., Dec. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics and PanTher Therapeutics have each won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge, Mass. facility on Dec. 11, 2018. Six finalists pitched their business plans to attendees where the audience members' votes served as input...
Source: Amgen News Release - December 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
Filing for ABP 710, a Biosimilar Candidate to Infliximab, Supported by Phase 3 Study in Patients With Moderate-to-Severe Rheumatoid Arthritis THOUSAND OAKS, Calif., Dec. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE® (infliximab). "At Amgen, we have spent nearly four decades developing, manufacturing and producing transformative medicines. We're leveraging our deep expertise and heritage in biologics to produce a portfolio of biosimilars t...
Source: Amgen News Release - December 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news